CRISPR Therapeutics AG (CRSP) Tax Provisions (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Tax Provisions of $839000.0 for Q1 2026, up 398.58% sequentially from -$281000.0 in Q4 2025, and down 23.73% YoY from $1.1 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Tax Provisions (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Tax Provisions for 12 years, with the latest figure at $839000.0 in Q1 2026.
- Quarterly Tax Provisions fell 23.73% year-over-year to $839000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 37.9% YoY) and the FY2025 annual result came in at $2.7 million, down 24.2% from the prior year.
- Tax Provisions climbed to $839000.0 in Q1 2026 per CRSP's latest filing, from -$281000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $6.1 million in Q2 2022 and troughed at -$9.5 million in Q4 2022.
- A 5-year average of $568058.8 and a median of $839000.0 in 2026 frame the typical range for Tax Provisions.
- The widest YoY moves for Tax Provisions: up 527.48% in 2022, down 320.59% in 2022.
- Over 5 years, Tax Provisions stood at -$9.5 million in 2022, then soared by 101.98% to $188000.0 in 2023, then surged by 272.34% to $700000.0 in 2024, then slumped by 140.14% to -$281000.0 in 2025, then jumped by 398.58% to $839000.0 in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $839000.0, -$281000.0, and $619000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 839,000.00 |
| Dec 31, 2025 | -281,000.00 |
| Sep 30, 2025 | 619,000.00 |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 876,000.00 |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 724,000.00 |
| Dec 31, 2023 | 188,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 923,000.00 |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | -9.48 Mn |
| Sep 30, 2022 | -575,000.00 |
| Jun 30, 2022 | 6.10 Mn |
| Mar 31, 2022 | 3.61 Mn |
| Dec 31, 2021 | -2.25 Mn |
| Sep 30, 2021 | -600,000.00 |